Appili Therapeutics Inc.

About Appili Therapeutics Inc.

Appili Therapeutics is dedicated to tackling serious global challenges in infectious diseases by delivering innovative drug development programs for unmet patient needs. The company focuses on advancing drug development in infectious disease and biodefense to provide solutions to patients, doctors, and society.

Products & Services

LIKMEZ™ (ATI-1501):A novel oral taste-masked suspension of metronidazole to treat serious anaerobic and protozoal infections.

ATI-1701:A potential first-in-class live-attenuated vaccine for tularemia, a serious biothreat.

ATI-1801:A novel topical antiparasitic product to treat disfiguring skin infections worldwide.

Specialties

Infectious Disease Drug Development Biodefense Anti-Infectives Infectious Disease Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-Brokered Private Placement T: - FT: Non-Brokered Private Placement	A: 177500 MR: - FA: C$177,500 FAN: 177500	D: 2025-12-18 FD: 2025-12-18	-
2	RT: Non-Brokered Private Placement T: - FT: Non-Brokered Private Placement	A: 750000 MR: - FA: up to approximately C$750,000 FAN: 750000	D: 2025-11-05 FD: 2025-11-05	-
3	RT: Federal Grant Proposals T: - FT: Federal Grant Proposals	A: 117500000 MR: - FA: US$117.5 million FAN: 117500000	D: 2025-03-18 FD: 2025-03-18	2 investors
4	RT: Government Grant T: - FT: Government Grant	A: 117500000 MR: - FA: US$117.5 million FAN: 117500000	D: 2025-03-18 FD: 2025-03-18	2 investors
5	RT: Grant T: - FT: Grant	A: 117500000 MR: - FA: 117.5 million FAN: 117500000	D: 2025-03-18 FD: 2025-03-18	-
6	RT: Bridge Loan T: - FT: Bridge Loan	A: 300000 MR: - FA: C$300,000 FAN: 300000	D: 2024-04-26 FD: 2024-04-26	1 investors
7	RT: Grant T: - FT: Grant	A: 6600000 MR: - FA: US$6.6 million FAN: 6600000	D: 2023-10-25 FD: 2023-10-25	2 investors
8	RT: Contract T: - FT: Contract	A: 7300000 MR: - FA: US$7.3 million FAN: 7300000	D: 2023-05-11 FD: 2023-05-11	2 investors

Non-Brokered Private Placement Latest

2025-12-18

$178K

Non-Brokered Private Placement 2025-11-05

$750K

Federal Grant Proposals 2025-03-18

$117.5M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Don Cilla

President and Chief Executive Officer

K

Kenneth Howling

Acting Chief Financial Officer

G

Gary Nabors

Chief Development Officer

A

Art Baran

Director, New Product Development

C

Carl Gelhaus

Director, Non-Clinical Research

L

Leona Saunders

Director, Regulatory Affairs

View 8 more team members with Pro

Unlock Full Team Directory

Recent News